Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.

ABSTRACT:

Purpose

Patients with chronic lymphocytic leukemia (CLL) with high-risk genomic features achieve poor outcomes with traditional therapies. A phase I study of a pharmacokinetically derived schedule of flavopiridol suggested promising activity in CLL, irrespective of high-risk features. Given the relevance of these findings to treating genetically high-risk CLL, a prospective confirmatory study was initiated.

Patients and methods

Patients with relapsed CLL were treated with single-agent flavopiridol, with subsequent addition of dexamethasone to suppress cytokine release syndrome (CRS). High-risk genomic features were prospectively assessed for response to therapy.

Results

Sixty-four patients were enrolled. Median age was 60 years, median number of prior therapies was fo

SUBMITTER: Lin TS 

PROVIDER: S-EPMC2793044 | biostudies-literature | 2009 Dec

REPOSITORIES: biostudies-literature